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Background
Designed for innovative HIV-1 diagnostics and resistance
analysis, a high-throughput laboratory-developed (Pro-
tease-Reverse-Transcriptase) genotyping assay was imple-
mented at Virco (Belgium). Following regulatory
guidelines, assay variability was monitored over time by
means of a quarterly internal quality control (QC) panel.
Methods
The panel comprises seven well-characterized recom-
binant viruses that were derived from clinical isolates.
Virus stocks were grown and later re-cultured as needed
and aliquoted for use at each quarterly testing between Q4
in 2001 through Q1 in 2007. The nucleotide similarity
among the original virus stocks and subsequent re-cul-
tured viruses, was determined using pairwise BLAST anal-
ysis (BioEdit Sequence Alignment Editor).
Summary of results
A total of 603 and 867 pairwise BLAST comparisons were
made, yielding an average within and between original
and re-cultured virus stocks similarity of 99.60% ± 0.27
and 99.52% ± 0.33, respectively.
Conclusion
Since both BLAST values did not differ, it can be con-
cluded that re-culturing of viruses did not lead to a signif-
icant decrease in similarity. Furthermore, despite the
presence of high levels of nucleotide sequence mixtures of
the original clinical isolates, the high reproducibility of
the genotyping assay (more than 99% sequence identity)
was demonstrated. A combination of optimal assay
design, rigorous personnel training, the testing of the
internal QC panel at regular intervals and participation in
a CLIA-approved 6-monthly external proficiency testing
program (Accutest) ensures that quality standards are con-
sistently met for the genotyping assay performed at Virco.
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